SCHEMBL9905577

SCHEMBL9905577

FC(F)(F)c1cc(Oc2ccc(CCBr)cc2)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 8/20 0.48
IDO1 P14902 2/20 0.48
RAF1 P04049 2/20 0.44
BRAF P15056 2/20 0.44
AR P10275 1/20 0.43
GPR84 Q9NQS5 1/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
FFAR1 O14842 1/20 0.40
CHEK2 O96017 2/20 0.39
KDR P35968 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108206 0.88 IDO1 (0.50) PLA2G7IDO1RAF1BRAFAR
SCHEMBL9901378 0.87 IDO1 (0.49) PLA2G7IDO1RAF1BRAFAR
SCHEMBL9106976 0.87 IDO1 (0.49) PLA2G7IDO1RAF1BRAFAR
SCHEMBL17226673 0.85 IDO1 (0.48) PLA2G7IDO1RAF1BRAFAR
SCHEMBL875568 0.85 IDO1 (0.48) PLA2G7IDO1RAF1BRAFAR
SCHEMBL9105104 0.85 IDO1 (0.51) PLA2G7IDO1RAF1BRAFAR
SCHEMBL9107327 0.85 IDO1 (0.51) PLA2G7IDO1RAF1BRAFAR
SCHEMBL29918301 0.85 IDO1 (0.48) PLA2G7IDO1RAF1BRAFAR
SCHEMBL875588 0.83 IDO1 (0.51) PLA2G7IDO1RAF1BRAFAR
SCHEMBL18235653 0.83 PLA2G7 (0.46) PLA2G7IDO1RAF1BRAFAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
EP-2649050-A1 COMPOUNDS Glaxo Group Limited (GB) 2013-10-16 EP disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
WO-2012075917-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-14 WO disclosed
WO-2012075917-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252986-A1 COMPOUNDS LIPG, ENPP2, PLA2G1B PLA2G7 6/4885IDO1 2470/4885RAF1 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.